Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001901060 | SCV002164772 | likely pathogenic | not provided | 2024-05-15 | criteria provided, single submitter | clinical testing | This sequence change affects an acceptor splice site in intron 8 of the GPAA1 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in GPAA1 are known to be pathogenic (PMID: 29100095). This variant is present in population databases (rs187027021, gnomAD 0.04%). This variant has not been reported in the literature in individuals affected with GPAA1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1394986). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Experimental studies and prediction algorithms are not available or were not evaluated, and the effect of this variant on mRNA splicing is currently unknown. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
3billion, |
RCV002051976 | SCV002318826 | likely pathogenic | Glycosylphosphatidylinositol biosynthesis defect 15 | 2022-03-22 | criteria provided, single submitter | clinical testing | Canonical splice site: predicted to alter splicing and result in a loss or disruption of normal protein function through nonsense-mediated decay (NMD) or protein truncation. Multiple pathogenic variants are reported downstream of the variant. The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency:0.0000867). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. |